CFTR and cystic fibrosis: Vanzacaftor–Tezacaftor–Deutivacaftor therapy has been approved for CF patients aged six and above, demonstrating significant increases in lung function and the correction of the defective CFTR protein, alongside a reduction in sweat chloride levels [59].